Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

NCT00248157 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

105

Enrollment

INDUSTRY

Sponsor class

Stopped Inconsistent treatment benefit

Conditions

Diabetic Retinopathy

Interventions

DRUG: Octreotide acetate in microspheres

Sponsor

Novartis Pharmaceuticals